The Effect of Finasteride on Vascular Endothelial Growth Factor (VEGF) Expression in the Prostate Tissue and Bleeding Volume during Trans Urethral Resection of the Prostate (TURP)

This study was evaluated the efficacy of Finasteride as a neoadjuvant therapy in reducing bleeding volume in patients with Benign Prostatic Hyperplasia (BPH) and urinary retention with prostate volume 30-50 mL who underwent Trans Urethral Resection of the Prostate (TURP). The study respondent consisted 26 patients with BPH and urinary retention who planned to undergo TURP. The study sample was randomly split into 2 treatment groups, 13 patients received Finasteride 5 mg once daily for 2 to 4 weeks before the operation and 13 others defined as control group. The therapy efficacy is evaluated by comparing the Haemoglobin pre-post operation difference, bleeding volume, bleeding volume per gram prostate tissue resected and the Vascular Endothelial Growth Factor (VEGF) expression within the prostate tissue. The treatment group indicated difference Haemoglobin between pre and post operation and average bleeding volume has less significant than the control group. The treatment group showed less amount of bleeding volume per gram of prostate tissue resected compare to control group. The treatment group also found significant lower VEGF expression within prostate tissue than the control group. This study demonstrated Neoadjuvant therapy with finasteride 1 x 5 mg for 2 to 4 weeks can reduce the VEGF expression in prostate tissue and reduce bleeding volume due to TURP